Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACTROBAN vs ALTABAX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Impetigo due to Staphylococcus aureus and Streptococcus pyogenes,Mupirocin-sensitive infections
FDA-approved for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes in patients aged 9 months and older
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Minimal systemic absorption; rapidly metabolized to monic acid (inactive) in skin and systemically.
Retapamulin undergoes hepatic metabolism primarily via cytochrome P450 (CYP) isoenzymes, including CYP3A4, and is excreted in feces and urine.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
95% bound, primarily to albumin
Retapamulin is approximately 94% bound to human plasma proteins, primarily albumin.
0.15-0.3 L/kg, indicating distribution primarily into extracellular fluid
Volume of distribution after IV administration is approximately 3.1 L/kg, indicating extensive tissue distribution.
Topical: Negligible systemic absorption (<0.05% after topical application to intact skin; slightly higher (up to 1%) on abraded skin; intranasal: <0.1%
Systemic bioavailability after topical application is low and highly variable, with mean values <2% in adults.
No dosage adjustment necessary for topical application. For intranasal use, no adjustment required. Systemic absorption is minimal.
No dose adjustment required for renal impairment as systemic absorption is negligible.
No dosage adjustment necessary for topical or intranasal use. Systemic absorption is minimal.
No dose adjustment required for hepatic impairment as systemic absorption is negligible.
Children 3 months and older: Same as adult dosing. Topical: apply 2% ointment/cream three times daily for 5 to 14 days. Intranasal: apply 0.5 g of 2% ointment to each nostril twice daily for 5 days.
Children 9 months and older: Apply 1% ointment to affected area twice daily for 5 days. Maximum treatment area 100 cm². For children under 9 months: safety and efficacy not established.
No specific adjustments required. Use same dosing as adults. Caution in patients with renal impairment due to potential accumulation of polyethylene glycol vehicle with extensive use on open wounds or burns.
No specific dose adjustment required. Use same as adult dosing due to minimal systemic absorption.
None.
No black box warnings.
Severe allergic reactions including anaphylaxis and angioedema; potential for superinfection with prolonged use; not for intranasal use except specific formulations.
Not for use on mucous membranes (e.g., eyes, mouth, vagina).,May cause application site reactions (e.g., pruritus, erythema, pain).,Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including retapamulin.,Prolonged use may result in overgrowth of nonsusceptible organisms.
Known hypersensitivity to mupirocin or any component of the formulation.
Hypersensitivity to retapamulin or any component of the formulation.
No known food interactions. The drug is applied topically; oral intake does not affect its action.
None known. Topical application with negligible systemic absorption; no dietary restrictions.
No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.
No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 times MRHD) showed no fetal harm. However, systemic absorption after topical application is minimal, so fetal exposure is negligible. Risk cannot be ruled out; classify as pregnancy category B.
Unknown if excreted in human milk; caution advised. M/P ratio not established.
Not known if retapamulin is excreted in human milk. Systemic absorption is negligible after topical use, so risk to infant is likely low. M/P ratio not determined. Caution if applied to breast area to avoid infant ingestion.
No dose adjustments recommended; systemic absorption is minimal.
No dose adjustment needed. Pharmacokinetics unchanged as systemic absorption is minimal (<1%) and not affected by pregnancy. Standard dosing: apply thin layer to affected area twice daily for 5 days.
BACTROBAN (mupirocin) is a topical antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes. It is contraindicated for use on burns or large open wounds due to risk of polyethylene glycol absorption. For impetigo, apply to affected area three times daily for 5-10 days. Not effective against fungal, viral, or anaerobic infections. Monitor for local irritation; discontinue if severe. Use intranasal formulation (BACTROBAN Nasal) for MRSA decolonization.
Retapamulin (Altabax) is a topical pleuromutilin antibiotic indicated for impetigo due to S. aureus or S. pyogenes. Apply to lesions twice daily for 5 days. Avoid contact with eyes, mouth, or mucous membranes. No systemic absorption significant; safe for use in children ≥9 months. Do not use on open wounds or burns. Monitor for local irritation; discontinue if hypersensitivity occurs.
Apply a small amount of ointment to the affected area 3 times daily, or as directed.,Wash hands before and after application to prevent spreading infection.,Do not use on large areas of broken skin or deep wounds without medical advice.,Avoid contact with eyes and mucous membranes.,Complete the full course of treatment even if symptoms improve.,Stop use and contact doctor if rash or irritation occurs.,Do not share this medication with others.
Apply a thin layer to the affected area twice daily for 5 days, even if symptoms improve.,Wash hands before and after application unless treating hand lesions.,Do not cover the area with bandages unless instructed by your doctor.,Avoid getting the ointment in your eyes, nose, mouth, or on vaginal area.,Stop use and inform your doctor if you develop severe irritation, redness, or swelling.,Store at room temperature away from heat and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACTROBAN vs ALTABAX, answered by our medical review team.
BACTROBAN is a Topical Antibiotic that works by Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.. ALTABAX is a Topical Antibiotic that works by Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACTROBAN and ALTABAX depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACTROBAN is: Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.. The standard adult dose of ALTABAX is: 1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACTROBAN and ALTABAX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACTROBAN is classified as Category C. No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.. ALTABAX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 time. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.